Shares of Biogen BIIB, +3.22% fell 3% after it released additional data about its recently resurrected Alzheimer’s disease drug candidate. A fresh take on data from two Phase 3 trials for aducanumab showed that patients in the Emerge trial who received a high dose of the therapy reported reduced clinical decline, meeting the trial’s first and secondary endpoints. The Engage trial did not report a reduction in clincial decline. The biotechnology company had said in March that it would scrap trials for aducanumab after a futility analysis indicated that the drug would not meet the studies’ primary endpoints. The stock sunk to its lowest point, $216.71, in 2019 the day after that announcement. But then in a surprise move, Biogen said in October it would seek Food and Drug Administration approval for aducanumab early next year following discussions with the regulator using a larger dataset than what was used in the futility analysis. Biogen shares have fallen about 3% year-to-date, compared to the S&P 500 SPX, -0.02%, which is up about 24%.